Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 116

1.
2.

Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation.

Shepherd J, Brodin H, Cave C, Waugh N, Price A, Gabbay J.

Health Technol Assess. 2004 Oct;8(39):iii-iv, 1-125. Review.

3.

Factors affecting early viral load decline of Asian chronic hepatitis C patients receiving pegylated interferon plus ribavirin therapy.

Hsu CS, Liu CH, Liu CJ, Chen CL, Lai MY, Chen PJ, Chen DS, Kao JH.

Antivir Ther. 2009;14(1):45-54.

PMID:
19320236
4.

Chronic hepatitis C: treatment of pegylated interferon/ribavirin nonresponders.

Shiffman ML.

Curr Gastroenterol Rep. 2006 Feb;8(1):46-52. Review.

PMID:
16510034
5.
6.

Prediction of sustained virological response in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD) and ribavirin.

Foster GR, Fried MW, Hadziyannis SJ, Messinger D, Freivogel K, Weiland O.

Scand J Gastroenterol. 2007 Feb;42(2):247-55.

PMID:
17327945
7.

Baseline serum low-density lipoprotein cholesterol levels predict response to hepatitis C virus therapy in HIV/hepatitis C virus coinfected patients.

del Valle J, Mira JA, de los Santos I, López-Cortés LF, Merino D, Rivero A, Girón JA, Ríos-Villegas MJ, González-Serrano M, Collado A, García-García JA, Pineda JA.

AIDS. 2008 May 11;22(8):923-30. doi: 10.1097/QAD.0b013e3282ff8ad3.

PMID:
18453851
8.

Chronic hepatitis C: management of treatment failures.

Keeffe EB.

Clin Gastroenterol Hepatol. 2005 Oct;3(10 Suppl 2):S102-5. Review.

PMID:
16234055
9.
10.

The evolving treatment of chronic hepatitis C: where we stand a decade out.

Saadeh S, Davis GL.

Cleve Clin J Med. 2004 May;71 Suppl 3:S3-7. Review.

PMID:
15468610
11.
12.

Recurrent hepatitis C after liver transplantation: on-treatment prediction of response to peginterferon/ribavirin therapy.

Hanouneh IA, Miller C, Aucejo F, Lopez R, Quinn MK, Zein NN.

Liver Transpl. 2008 Jan;14(1):53-8.

13.

Management of patients with chronic hepatitis C virus infection and previous nonresponse.

Shiffman ML.

Rev Gastroenterol Disord. 2004;4 Suppl 1:S22-30. Review.

PMID:
15184821
14.

Relapse to prior therapy is the most important factor for the retreatment response in patients with chronic hepatitis C virus infection.

Sagir A, Heintges T, Akyazi Z, Oette M, Erhardt A, Häussinger D.

Liver Int. 2007 Sep;27(7):954-9.

PMID:
17696934
15.

Risk factors for relapse in chronic hepatitis C patients who have achieved end of treatment response.

Shin SR, Sinn DH, Gwak GY, Choi MS, Lee JH, Koh KC, Yoo BC, Paik SW.

J Gastroenterol Hepatol. 2010 May;25(5):957-63. doi: 10.1111/j.1440-1746.2009.06176.x. Erratum in: J Gastroenterol Hepatol. 2010 Aug;25(8):1468. Cho, Moon Seok [corrected to Choi, Moon Seok].

PMID:
20546450
16.

Pegylated alpha-interferon-2a plus ribavirin compared with pegylated alpha-interferon-2b plus ribavirin for initial treatment of chronic hepatitis C virus: prospective, non-randomized study.

Escudero A, Rodríguez F, Serra MA, Del Olmo JA, Montes F, Rodrigo JM.

J Gastroenterol Hepatol. 2008 Jun;23(6):861-6. doi: 10.1111/j.1440-1746.2008.05397.x. Epub 2008 Apr 19.

PMID:
18422960
17.
18.

Customizing treatment to patient populations.

Brown RS Jr.

Nat Clin Pract Gastroenterol Hepatol. 2007 Jan;4 Suppl 1:S3-9. Review.

PMID:
17235282
19.

[New trend in treatment in patients with chronic hepatitis C].

Werling K, Tulassay Z.

Orv Hetil. 2006 Apr 9;147(14):637-41. Review. Hungarian.

PMID:
16711370
20.

Response-guided therapy for chronic hepatitis C virus infection in patients coinfected with HIV: a pilot trial.

Van den Eynde E, Crespo M, Esteban JI, Jardi R, Ribera E, Carbonell J, Rodríguez-Frias F, Falco V, Curran A, Imaz A, Villar del Saz S, Ocaña I, Esteban R, Pahissa A.

Clin Infect Dis. 2009 Apr 15;48(8):1152-9. doi: 10.1086/597470. Erratum in: Clin Infect Dis. 2009 Aug 1;49(3):489.

Items per page

Supplemental Content

Write to the Help Desk